" class="no-js "lang="en-US"> Huyabio International Collaboration with Bristol Myers Squibb in Melanoma - Medtech Alert
Wednesday, February 08, 2023

Breaking News

Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, a Rare Life-threatening Blood Condition Ultima Genomics and Integrated DNA Technologies to Enable Application Portfolio on Ultima Sequencing Platforms Radiology Imaging Associates Launches the Enhanced Breast Cancer Detection Program
Huyabio International Collaboration with Bristol Myers Squibb in Melanoma | Pharmtech Focus

March 30 2021

Huyabio International Collaboration with Bristol Myers Squibb in Melanoma

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy of the combination in subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy.

“This Phase 3 trial follows our open label Phase 2 study which showed impressive clinical results for the combination of Opdivo and HBI-8000 to treat melanoma,” said Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO. “HBI-8000 has been shown to enhance the efficacy of Opdivo through one of its mechanisms of action that controls acetylation and nuclear transportation of PD-L1.”

HUYABIO will be the sponsor of the trial. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study. Opdivo® is a registered trademark of Bristol Myers Squibb.

People In This Post

Mireille Gillings

Mireille Gillings

Companies In This Post

Huyabio International | Pharmtech Focus

Huyabio International
  1. Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer

    Appointments

     Read more
  2. Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.

    News

     Read more
  3. Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth

    Fundraising

     Read more
  4. Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer

    Appointments

     Read more
  5. TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials

    Fundraising

     Read more
More On